Although Macalpine and Hunter 4 are supported by Rohl, Warren and Hunt, 5 Holmes' contrary view needs to be made known to a wider readership than those who have read his book.
Selective cyclo-oxygenase-2 (COX-2) inhibitors, sometimes referred to as 'coxibs', are widely prescribed by hospital doctors and general practitioners for arthritic pain. Their gastrointestinal tolerability is believed to be superior to that of 'non-selective' non-steroidal anti-inflammatory drugs (NSAIDs) such as naproxen and diclofenac. Since the US Food and Drug Administration (FDA) approved the use of rofecoxib (Vioxx) in May 1999, 83 million prescriptions have been issued worldwide. However, on 30 September 2004, rofecoxib was voluntarily withdrawn by Merck Sharp & Dohme because of an increased relative risk of serious cardiovascular events seen after 18 months' use in the APPROVe (Adenomatous Polyp Prevention On Vioxx) trial. The APPROVe trial was initiated because of two previous studies 1,2 indicating that daily aspirin had protective effects against colorectal adenomas.
The finding of increased risk of cardiovascular events in relation to rofecoxib did not come as a complete surprise. Such an effect was evident in the Vioxx Gastrointestinal Outcomes Research (VIGOR) 3 study, the results of which were reported almost 4 years ago. Results for the first 6 months from a similarly large trial of another selective COX-2 inhibitor, the Celecoxib Long-term Arthritis Safety Study (CLASS), 4 suggested that celecoxib had a better gastrointestinal toxicity profile than diclofenac or ibuprofen but results for the 12 month period, made available on the FDA website, 5 do not entirely support this conclusion. The discrepancy generated criticism of the way the CLASS data were initially reported. 6 Moreover, although celecoxib was not associated with a higher risk of serious cardiac sequelae than diclofenac or ibuprofen over the whole duration of the trial, the data do not exclude the possibility of lesser effects related to cardiac ischaemia.
When an unexpected drug effect is observed, whether adverse or beneficial, the possibility of a 'class-effect' has to be considered. So, might adverse cardiovascular effects be expected with COX-2 agents other than rofecoxib? This question will need to be addressed with complete transparency in future studies of COX-2 inhibitorsespecially with the advent of agents such as valdecoxib (Bextra), the successor drug of celecoxib, and etoricoxib (Arcoxia), planned successor of the withdrawn rofecoxib. Meanwhile, for the purposes of alleviating arthritic pain at least, COX-2 inhibitors have lost some of their attraction compared with the older NSAIDs such as diclofenac in combination with a proton pump inhibitor (omepraxole). 7 In their paper about the therapeutic potential of adult bonemarrow stem cells (October 2004 JRSM 1 ) Professor Hassan and Dr El-Sheemy refer to ethical controversies over use of embryonic stem cells. Apart from the ethical objections, cell replacement therapy from embryos and fetal tissue is complicated by difficulties with standardizing the procedure, ensuring viability of tissue and obtaining tissue at optimal time points. By induction of fate-specific cells from an in-vitro-expanded population of isolated progenitor/stem cells, bone marrow stem cells may be more readily exploited. Differentiation of expanded cells can be induced by mitogen withdrawal or by exposure to cytokines, hormones or vitamins that cause lineage restriction. Cytokines involved in the clonal expansion and lineage restriction of stem/progenitor cells in the haematopoietic system may play an important analogous role in the developing nervous system. For example, interleukin-1 can induce expression of the dopaminergic marker tyrosine hydroxylase. Furthermore, in a study by Carpenter et al. 2 leukaemia inhibitory factor, a member of the interleukin-6 cytokine family, when combined with other mitogens was shown to enhance proliferation of human forebrain neural stem cells. Importantly, we need to consider the possibility that bone marrow stem cells are able to redifferentiate. Already there is evidence that neural stem cells can become bone-marrow-like: they were shown capable of reconstituting the haematopoietic systems of mice that had undergone marrow ablation. 3 These studies suggest that the lineage path taken by multipotent cells is influenced by the environments to which they are exposed. An immediate consequence was that the 'risk management' section of our trust expressed grave concern that diathermy (bipolar in our case) was being used in our department. Within a fortnight a departmental policy was created stating that diathermy may be made available only if all attempts at controlling bleeding with ligatures have failed. When does that point arrive? If one tries hard enough and keeps on ligating every red object in the tonsillar bed, all bleeds eventually stop. The surgeon now feels guilty even about mentioning diathermy.
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Having looked at the 'evidence', I wonder why NICE was in such a hurry to release this interim guideline before reaching definitive conclusions. Take the chart providing figures for 'cold steel dissection with diathermy haemostasis' (the method I use). No distinction is made between monopolar and bipolar types even though the audit form differentiates between the two. We are told that patients operated in this way are 0.7% more likely to return to theatre with postoperative bleeding than those in whom ligatures only are used. Since the document later states that the monopolar type is twice as harmful as the bipolar type, we might reasonably assume that in patients receiving bipolar diathermy for haemostasis the excess risk of returning to theatre will be even less than 0.7%. Should we really change our practice on the basis of this very small difference and lose the advantages that bipolar haemostasis has to offer-notably, a much quicker operation and less preoperative blood loss (both matters on which the 'interim guidance' is silent)? The practical advantages of bipolar dissection have been well discussed by Silveira et al. 1 In presenting its haemorrhage figures, NICE states that patients operated upon by trainees are roughly twice as likely to bleed as those operated on by non-training grades and consultants. Unfortunately, this difference is not allowed for in discussion of individual methods. If, for example, cold steel tonsillectomy with ligature haemostasis is done mainly by experienced surgeons while the younger generation favour diathermy, that might explain the apparent advantages of the former. Many aspects of the interim guidance are in conflict with recent studies. Both Belloso et al. 2 and Timms 3 have reported lower rates of postoperative bleeding with coblation than with cold-steel dissection and bipolar haemostasis. Moreover, in a review of the published work, Leinbach et al. 4 showed no significant difference in postoperative bleeding between monopolar dissection and cold steel dissection.
By presenting its confusing interim guidance NICE breached a basic principle of audit that changes are effected only after the data collection phase of the audit is over; otherwise the final assessment is falsified. For example, whereas before the guidelines nearly all the tonsillectomies at our hospital involved diathermy, the procedure is now almost extinct -yet the data collection phase is yet not over. As it happens, the number of post-tonsillectomy bleeds has slightly increased, though (as with some of the differences in the NICE document) this may be due to chance.
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